Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 294-305 http://medscipublisher.com/index.php/cge 305 Vidula N., Rich T., Sartor O., Yen J., Hardin A.I., Nance T., Lilly M.B., Nezami M.A., Patel S.P., Carneiro B.A., Fan A.C., Brufsky A.M., Parker B.A., Bridges B.B., Agarwal N., Maughan B.L., Raymond V.M., Fairclough S.R., Lanman RB, Bardia A., and Cristofanilli M., 2020, Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors, Clinical Cancer Research, 26(9): 2546-2555. https://doi.org/10.1158/1078-0432.CCR-19-2933 Walton J., Blagih J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman L.A., Orange C., Athineos D., Mason S., Stevenson D., Blyth K., Strathdee D., Balkwill F.R., Vousden K., Lockley M., and McNeish I.A., 2016, CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma, Cancer Research, 76(20): 6118-6129. https://doi.org/10.1158/0008-5472.CAN-16-1272 PMID: 27530326 PMCID: PMC5802386 Wang Y.F., Bernhardy A.J., Cruz C., Krais J.J., Nacson J., Nicolas E., Peri S., van der Gulden H., van der Heijden I., O’Brien S.W., Zhang Y., Harrell M.I., Johnson S.F., Candido dos Reis F.J., Pharoah P., Karlan B., Gourley C., Lambrechts D., Chenevix-Trench G., Olsson H., Benitez J.J., Greene M.H., Gore M., Nussbaum R., Sadetzki S., Gayther S.A., Kjaer S.K., Investigators C., D'Andrea A.D., Shapiro G.I., Wiest D.L., Connolly D.C., Daly M.B., Swisher E.M., Bouwman P., Jonkers J., Balmaña J., Serra V., and Johnson, N., 2016, The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin, Cancer Research, 76(9): 2778-2790. https://doi.org/10.1158/0008-5472.CAN-16-0186 PMID: 27197267 PMCID: PMC4874568 Wolf D., Fiegl H., Zeimet A.G., Wieser V., Marth C., Sprung S., Sopper G., Hartmann G., Reimer D., and Boesch M., 2019, High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome, International Journal of Cancer, 146(7): 2007-2018. https://doi.org/10.1002/ijc.32818 PMID: 31800094 PMCID: PMC7028124 Xie W.W., Sun H.Z., Li X.D., Lin F.K., Wang Z.L., and Wang X.P., 2021, Ovarian cancer: epigenetics, drug resistance, and progression, Cancer Cell International, 21(1): 434. https://doi.org/10.1186/s12935-021-02136-y PMID: 34404407 PMCID: PMC8369623 Yahya S., Mohamed S., and Yahya, S.M.M., 2022, Gene editing: a powerful tool for cancer immunotherapy, Biointerface Research in Applied Chemistry, 13(1): 98. https://doi.org/10.33263/briac131.098 Yamanaka Y., 2016, CRISPR/Cas9 genome editing as a strategy to study the tumor microenvironment in transgenic mice, Methods in Molecular Biology, 1458: 261-271. https://doi.org/10.1007/978-1-4939-3801-8_19 PMID: 27581028 Zanini E., Louis L.S., Antony J., Okon I., McKie A.B., Recchi C., and Gabra H., 2017, The tumour suppressor protein OPCML acts as a sensitizing agent in anti-EGFR/HER2 therapy and cisplatin treatment in ovarian cancer, Clinical Cancer Research, 23(11_Supplement): NTOC-116. https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-116
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==